Australian pollen season may be arriving early in eastern states Medical Xpress Has hay fever season started early? And what’s the most common culprit? The Conversation What you need to know about seasonal illnesses this spring SBS Expat reveals health condition that's much worse in Australia: 'Every night at 4am' au.news.yahoo.com
Google News
Original source
yahoo
Check live status on DownRightNow
Ever wondered what a doctor who specializes in obesity medicine eats? We asked one to share their day of eating with us.
REDWOOD CITY, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- AirNexis Therapeutics, Inc. ("AirNexis"), a clinical-stage biotech company developing therapeutics for pulmonary diseases, today announced results from a Phase 2b study of AN01, a dual PDE3/4 inhibitor DPI. The study, HSK39004-T1-202, was conducted in China by AirNexis' partner Haisco Pharmaceutical Group ("Haisco"). The Phase 2b study enrolled patients with chronic obstructive pulmonary disease (COPD) receiving background therapy of single or dual bronchodilator maintenance therapy who remained symptomatic despite such treatment. Data were presented earlier today at the 2026 European Respiratory Society (ERS) Congress in Barcelona, Spain. The ePoster will be available on the conference's website. AirNexis licensed AN01 (HSK39004 in China) from Haisco, which is developing the asset for the Greater China market; AirNexis holds development rights outside China.
Dr Pauline Swift explains how to take an accurate reading.
Sam Eljamel was a consultant neurosurgeon at Ninewells Hospital from 1995 until his suspension in 2013.
Headlines and briefs on this site are for information only. Always verify details on the original source or live status page.
Read Disclaimer